Category Archives: Global

Measles Outbreak in UK: Why We Need to Maintain a Balance of Communication Power

By Guest Blogger | Published: April 22, 2013
The current UK measles outbreak reminds us that, as far as healthcare communication is concerned, the voice of the people is not necessarily the voice of God, writes Reflector. The localized outbreak of measles in the UK is alarming in more ways than one. There can only be sympathy for the victims of this sudden return [...]
Also posted in Europe, Guest Blog, Patient Communication, Technology, healthcare, patient education, social media | Tagged , , | Leave a comment

Tough Times Ahead for New Medicines under NHS England?

By Guest Blogger | Published: April 22, 2013
By Leela Barham You’d be forgiven for missing it with the vast array of new agencies and the policy documents, guidance, consultations and ‘engagement’ activity they’re doing on in the ‘new’ NHS in England, but on the 4th April NHS England (formerly the NHS Commissioning Board) set out 15 commissioning policies in 250 pages.  They’re important, [...]
Also posted in Europe, Guest Blog, healthcare, pricing | Tagged , , , , , | Leave a comment

Drug Pipelines in Canada: Is There a Buyer for Future Innovation?

By Clark Herman | Published: April 15, 2013
Last week, Canada’s National Prescription Drug Utilization Information System (NPDUIS), a federal-provincial fact-finding panel that works closely with the Patented Medicines Prices Review Board (PMPRB), issued its fourth New Drug Pipeline Monitor (NDPM) looking at drugs currently under development that may have an impact on future drug expenditures. The report is another example of how [...]
Also posted in IP, Market Access, Orphan Drugs, R&D, Regulatory, healthcare, pricing | Tagged , , , , , | Leave a comment

England's Cancer Drug Fund: An Acid Test for Value Based Pricing

By Guest Blogger | Published: April 12, 2013
By Leela Barham. England’s Cancer Drugs Fund (CDF) could be in its final financial year, after running in full since April 2011.  The fund covers the cost of cancer treatments either when NICE has said ‘no’, or hasn’t yet come to a view.  Companies can’t circumvent NICE though; if a company was invited to submit to [...]
Also posted in Europe, Guest Blog, Op-Ed, pricing | Tagged , , , , , | Leave a comment

Does India's Glivec Decision Make April Fools of Us All?

By Guest Blogger | Published: April 5, 2013
By Helen Disney, Pugatch Consilium. On April 1, India’s Supreme Court denied an appeal challenging the rejection of a patent for Novartis’s cancer drug, Glivec. The drug is a life-saving medicine for certain forms of cancer, patented in nearly 40 other countries — including many which are not noted for the strength of their intellectual property [...]
Also posted in Guest Blog, IP, Legal, Op-Ed | Tagged , , , | 2 Comments